The Center for Childhood Infections and Vaccines (CCIV) is addressing major childhood infectious diseases through innovative research into microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
The center has five integrative focus areas that are designed to build new collaborations, which will lead to sustainable research programs, new grant opportunities and important discoveries. You can learn more about these programs below.
Click "Newsletters & News" in the left menu to learn about the recent happenings of the center.
Monday Seminar Series
Join us for the CCIV Monday Seminars Series. View the most current Spring 2020 schedule.
UPDATE: During the COVID-19 remote work period, you can participate virtually via Zoom. Seminars will remain from 1-2 pm on Mondays virtually until further notice.
CCIV COVID-19 Research and Events
Our members are doing tremendous work to advance understanding of the coronavirus and move us closer to a vaccine or cure. Take a look at our current research efforts in the "SARS CoV-2 and COVID-19 Research Projects" and "In the News" sections below.
Kudos to Jens Wrammert and others for their work to develop a COVID-19 serologic test! Learn more here.
Thank you for helping to make the COVID-19 Pediatric Research Webinar a success!
This event drew over 200 registrants! Read what some of them valued most about the webinar...
- "The speakers were excellent"
- "It included the latest information and developments, provided good high-level information as well as practical details."
- "Great to have a better understanding of the current research areas."
- "Peter Hotez and summary of current stats from Anne Kimball. Mehul Suthar is fantastic. Loved the ability to watch remotely - this enabled me to listen to the entire event."
- "Well roundedness of things discussed. Not just the science but also policy and other things related to topic."
- "Very informative and provided most up-to-date information on COVID-19."
- "The opportunity to hear from an internationally recognized expert, Dr. Hotez."
- "CDC talk related to COVID in children and population and vaccination development"
We're so sorry if you missed it. The webinar was not recorded due to unpublished data that was presented.
CCIV Spring 2020 Newsletter
Current CCIV Member SARS CoV2 and COVID-19 Research Projects
Characterization of Cytokine, Genomic, and Transcriptomic Profiles Associated with Clinical Response Variability in Pediatric COVID-19 Patients
PIs: Ann Chahroudi, MD, PhD and Samya Chakravorty, PhD
Collaborators: Anne Spaulding, MD, MPH
COVID Convalescent Plasma to Optimize Treatment of COVID-19+ Patients at Very High Risk for Mortality Due to Immune or Pulmonary Disease
PIs: Cassandra Josephson, MD and Preeti Jaggi, MD
Collaborators: Kirsten Williams, MD; Inci Yildirim, MD, PhD; and John Roback, MD, PhD
Coronavirus disease 2019 (COVID-19) in Children & Young Adults with Cancer and Blood Diseases
PIs: Inci Yildirim, MD, PhD, MSc and Marianne Yee, MD
Collaborators: Larry Anderson, MD; Mark Gonzalez, PhD; and Pratik Patel, MD
CRISIS: COVID Risk Stratification Scoring System
PIs: Rajit K. Basu, MD, MS, FCCM
Collaborators: Rahul Damania, MD; Andi Shane, MD, MPH, MSc; Matt Linam, MD, MS; Preeti Jaggi, MD; Grace Gombolay, MD; Nabihah Mahmood, MD; and Kaitlin Jones, BSN, RN, CPEN
PI: Evan Anderson, MD
Collaborators: Kristy Rostad, MD; Jens Wrammert, MD; Larry Anderson, MD; Inci Yildirim, MD, PhD, MSc
Mechanism of SARS-CoV-2 Entry
PI: Gregory Melikian, PhD
Collaborators: Stefan Sarafianos, PhD; Larry Anderson, MD and Jens Wrammert, PhD
Pediatric Coronavirus Disease-19(COVID-19) Epidemiology and Outcomes
PIs: Preeti Jaggi, MD and Carol Kao, MD
Collaborators: Andi Shane MD, MPH, MSc and Matt Linam, MD
Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults
PI: Evan Anderson, MD
Collaborators: Inci Yildrim, MD, PhD, MSc; Christina Rostad, MD; and Carol Kao, MD
Remdesivir Use in Severe Pediatric COVID-19: A Case Series
PIs: Carol Kao, MD and Preeti Jaggi, MD
Collaborators: Omayma Amin, MD, MBBS and Andres Camacho-Gonzalez, MD
RSV in Older Adults and Pregnant Women Study (ROAPS)
PI: Evan Anderson, MD
Collaborators: Multiple including but not limited to Inci Yildirim, MD, PhD, MSc; Kristy Rostad, MD; Carol Kao, MD; and Larry Anderson, MD
Surveillance of Healthcare Workers for COVID-19 Antibodies
PIs: Claudia R. Morris, MD and Miriam B. Vos, MD, MSPH
Collaborators: Travis Sanchez, DVM, MPH; Patrick Sullivan, MD; Andres Camacho-Gonzalez, MD, MSc; Wendy Little, MD; Brittany Murray, MD; Srikant Iyer, MD, MPH; Brad Hanberry, PhD; Mehul Suthar, PhD; and Jens Wrammert, PhD
CCIV Members in the News!
May 7, 2020
Atlanta Journal-Constitution: Vast changes may be needed so children don’t spread COVID-19
May 4, 2020
ABC 7 - TheDenverChannel.com: Emory University in phase 1 of human clinical trials for SARS-CoV-2 vaccine
May 1, 2020
Atlanta Magazine: Emory University helps test the nation’s first potential COVID-19 vaccine and possible treatments
May 28, 2020
WABE: Doctors Report A New Condition In Kids With A Possible Link To COVID-19
May 26, 2020
WSB-TV2, Atlanta: New form of COVID-19 treatment drug could be used to help children
May 21, 2020
WXIA-TV 11 Alive, Atlanta: Emory makes major breakthrough in understanding COVID-19 antibodies - and testing for them
Futurity: Research News: COVID-19 patient antibodies may clarify immunity
May 20, 2020
WSB-TV2, Atlanta: Emory researchers locate antibodies that could neutralize COVID-19
Atlanta is a leading global center of infectious diseases research, including strengths at Emory University and the Centers for Disease Control and Preventions (CDC). Investigators from a number of additional institutions add to strengths in this area, including Georgia Tech, Morehouse School of Medicine, The University of Georgia, and Medical College of Georgia. Children’s Healthcare of Atlanta will build on these strengths through the CCIV, working with partner institutions in a new enterprise that focuses on microbial pathogenesis, immune responses in children, and the development of new vaccines and therapeutics.
To achieve the overarching goal of impacting child health on a global scale, CCIV will:
- Enhance understanding of infectious diseases, basic immunologic processes, and the development of vaccines and treatments against childhood pathogens.
- Build new collaborations and interdisciplinary projects leading to new extramural funding.
- Develop a program and critical mass of investigators focused on infectious diseases and emerging global health issues. We will integrate efforts within the CCIV with those at the Emory Vaccine Center, Emory Transplant Center, the Carter Center, the Emory Global Health Institute, and CDC initiatives. Participation in CCIV initiatives is open to investigators from these and other research institutions throughout the state of Georgia.
This program includes laboratories focused on basic biology and immunology of the following pathogens:
- Measles virus
- Respiratory syncytial virus (RSV)
- Viral and Bacterial Diarrheal Pathogens
- Structural basis of host-pathogen interactions
The innate immunity program focuses on basic aspects of the immune response to foreign antigens, including the early responses that change the adaptive immune responses. Novel adjuvants (stimulants of the innate response that can enhance vaccine efficacy) are one area of focus of this program.
Vaccine responses in young infants are complicated by an immature immune system and sometimes by the presence of maternal antibody. This program focuses on unique aspects of immunity in the developing fetus and the newborn infant, with the goal of enhancing the efficacy of vaccines given to infants.
The Global Infectious Diseases Program is focused on clinical research and interventions for pathogens that are major causes of childhood mortality in the developing world. Current areas of research by CCIV investigators in this Program include epidemiology and treatment for malaria and rotavirus vaccine efficacy in the developing world.
This program spans the spectrum of the vaccine development process, from the design and testing of new vaccines in the lab to the performance of human clinical trials. The program currently is focusing on vaccines against malaria, rhinovirus, respiratory syncytial virus, HIV/AIDS, Ebola, Zika, and influenza.
To support CCIV investigators as well as other investigators throughout the research centers several resource cores have been established:
Research Center Director Opportunity Fund
What is it? The Research Center Director Opportunity Fund is intended to provide modest support for a discrete opportunity that would otherwise be missed without this additional funding. It is intended to provide resources to investigators to remove barriers to research success.
Eligible requests include:
- Supply costs to generate preliminary data to support the submission of a new or revised NIH grant or for experiments requested by reviewers of a submitted manuscript
- Core services related to #1 or #2 above
- Publication fees for pilot grant funded projects
- Travel for study/research purposes
- Other types of requests may be considered on a case-by-case basis
Ineligible requests include:
- Salary/fringe costs to pay for effort
- Travel to conferences
Who is eligible? All faculty with membershp in CCIV.
How do I apply? Submit your written request to the Pediatric Research Alliance Sr. Business Manager, Shantisa Fulgham for review prior to submitting a request to CCIV Center Director, Ann Chahroudi, MD, PhD. The request should be no more than one page and include the following:
- Description of request
- Need justification (including a statement of why funds are not available from other sources)
- Proposed budget
- Attach an "other support" page to the request detailing any funds already received
When are funds awarded? Requests will be reviewed by the CCIV Center Director as received and decisions are anticipated to be made within a week or so.